Try our Advanced Search for more refined results

FTC Says FDA Biosimilar Naming Rules May Confuse Doctors

By Kurt Orzeck (October 28, 2015, 7:18 PM EDT) -- The U.S. Federal Trade Commission on Wednesday criticized the U.S. Food and Drug Administration's proposed rules requiring biosimilars to use unique names for their active ingredients, saying the rules might confuse doctors and deter them from prescribing biosimilars....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!